Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 30 August 2024, including: summer ADC dealmaking continues apace; a look at cell therapies in Japan; Pfizer Inc.’s new US digital consumer platform; Galapagos NV’s US point of care CAR-T study; and Novartis AG partners with Lindy Biosciences on biologics delivery.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Five Recent Deals Show ADCs Aren’t Cooling Off For Summer" - Scrip, 23 August, 2024.)
(Also see "Progress Or Hype? A Decade Of Cell Therapy In Japan" - Scrip, 26 August, 2024.)
(Also see "Pfizer Unveils New End-To-End Digital Consumer Platform" - Scrip, 27 August, 2024.)
(Also see "Galapagos Expands Point-Of-Care CAR-T Study To The US" - Scrip, 23 August, 2024.)
(Also see "Honey, I Shrunk The Drugs: Novartis, Lindy Partner On Biologics Delivery" - Scrip, 28 August, 2024.)
